A Comparison of the Effects of Exercise Methods for Adolescent Hyperkyphosis on the Sensorimotor System
NCT07922369, Not applicable, Not yet recruiting, Istanbul University - Cerrahpasa
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Comparison of the Effects of Exercise Methods for Adolescent Hyperkyphosis on the Sensorimotor System | ClinicalTrials.gov |
| NCT number | NCT07922369 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 58 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Istanbul University - Cerrahpasa | ClinicalTrials.gov |
| Conditions | Kyphosis Postural Thoracic, Kyphosis | ClinicalTrials.gov |
| Interventions | Kyphosis-Specific Schroth Exercise Program, Conventional Exercise Program | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Thoracic Extension Absolute Repositioning Error | At baseline and at the end of Week 8 | Thoracic position sense will be assessed with dual digital inclinometers placed at T1 and T12. With eyes closed, participants will reproduce a 15° thoracic extension target. The primary measure is the mean absolute difference between the target and reproduced angles across five trials, in degrees; lower values indicate smaller error. Flexion (30°) and right and left lateral flexion (20°) will also be measured as secondary directional outcomes. | ClinicalTrials.gov |
| Secondary | Balance | At baseline and at the end of Week 8 | Balance will be assessed with the AI Balance system using the modified Clinical Test of Sensory Interaction on Balance (four eyes-open/eyes-closed conditions on firm and foam surfaces; three 30-second trials per condition) and the Limits of Stability test (weight shifting toward eight targets). Higher sway index values indicate greater sway; higher Limits of Stability scores indicate better performance. | ClinicalTrials.gov |
| Secondary | Thoracic Curvature | At baseline and at the end of Week 8 | Thoracic curvature will be measured with a Flexicurve ruler from C7 to T12. The kyphosis index will be calculated as the kyphosis apex depth divided by the curve length, multiplied by 100. The values above 13 indicate hyperkyphosis. | ClinicalTrials.gov |
| Secondary | Sagittal Posture | At baseline and at the end of Week 8 | Sagittal posture will be assessed from a lateral photograph using the PostureScreen Mobile application. Landmark displacement will be recorded in centimeters under standardized camera, posture, clothing, and hair conditions. | ClinicalTrials.gov |
| Secondary | Muscle Strength | At baseline and at the end of Week 8 | Isometric strength of the trunk flexors and extensors, upper, middle, and lower trapezius, and serratus anterior will be measured using a hand-held dynamometer and the make-test method. Three 5-second contractions will be performed for each muscle group. Mean force will be normalized to body weight and reported in N/kg. | ClinicalTrials.gov |
| Secondary | Flexibility | At baseline and at the end of Week 8 | Hamstring and lower-back flexibility will be measured with the sit-and-reach test; the maximum distance across three trials will be recorded in centimeters. Pectoralis minor muscle length will be measured bilaterally with a tape measure; the mean of three measurements will be analyzed. | ClinicalTrials.gov |
| Secondary | Muscle Endurance | At baseline and at the end of Week 8 | Scapular, trunk flexor, and trunk extensor endurance will be assessed using the isometric scapular endurance, McGill trunk flexor endurance, and Biering-Sørensen tests, respectively. The time each position is maintained without compensation will be recorded in seconds. Each test will be performed once, with at least 5 minutes of rest between tests. | ClinicalTrials.gov |
| Secondary | Spinal Pain | At baseline and at the end of Week 8 | Resting, activity-related, and nocturnal spinal pain during the previous week will be rated on a 0-10 cm Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst possible pain. | ClinicalTrials.gov |
| Secondary | Deformity Perception | At baseline and at the end of Week 8 | Deformity perception will be assessed with the Turkish version of the Kyphosis-Specific Spinal Appearance Questionnaire. The 10-item questionnaire is scored from 1 to 5; the mean item score will be analyzed. Higher scores indicate a more negative perception of spinal appearance. | ClinicalTrials.gov |
| Secondary | Perceived Global Change | At the end of Week 8 | Overall perceived change will be assessed using the 7-point Global Rating of Change scale, from -3 (much worse) to +3 (much better), with 0 indicating no change. Scores of +2 or +3 will indicate a clinically meaningful perceived improvement. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)